New York, NY -- December 22, 2020 -- InvestorsHub NewsWire -- Traders News Source, a leading independent equity research and corporate access firm focused on small cap growth companies issues new research.

Anavex Life Sciences Corp. (NASDAQ: AVXL) is a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders including Alzheimer’s disease, Parkinson’s disease, Rett syndrome and other central nervous system (CNS) disorders. The company recently reported top-line results from a U.S. Phase 2 randomized, double-blind, placebo-controlled trial of ANAVEX®2-73 in adult female patients with Rett syndrome.
All twenty-five patients in this randomized study elected to enter a 12-week ANAVEX®2-73 extension study. Anavex will be advancing its Expanded Access Policy in order to provide long-term therapy to current participants with Rett syndrome under an expanded access program for ANAVEX®2-73.

Social Life Network, Inc. (OTCPINK: WDLF) is a Technology Business Incubator that provides tech start-ups with seed technology development, legal guidance, and executive leadership, making it easier for start-up founders to focus on raising capital, perfecting their business model, and growing their network usership. Social Life Network charges licensees a 5% fee on their profits, and a 15% stake in their company if they reach the liquidity event of going public or selling their business.
The company began with 4 cannabis centric social networks as clients.  Through 2020, they have licensed six additional niche social networks to tech start-ups in the Residential Real Estate industry, Hunting, Fishing and Camping industry, Racket Sports, Soccer, Golf and Cycling industries.

View our new biotech report with no obligation READ MORE
Copy and paste to browser may be required https://tradersnewssource.com/dynamic-biotech-coverage/


Revive Therapeutics Ltd. (OTCPINK: RVVTF) has recently provided an update on its oral thin-film delivery system with psilocybin being developed under a research partnership agreement with Reed Research Group out of the University of Wisconsin-Madison. “We are very pleased to have achieved this development milestone of our orally dissolvable thin film strip for psilocybin, which can be used in FDA human clinical studies and as a unique product for medical use in states where psilocybin therapy use is permitted, such as Oregon following the passage of Measure 109,” said Michael Frank, CEO of Revive.
There are a number of advantages and benefits of an orally dissolvable psilocybin thin film such as the rapid dissolving and onset of action to the bloodstream, the ease and convenience for patients to administer without the need of water, chewing or swallowing.

TELUS recently highlighted the newly consummated business partnership between TELUS and Ultrack Systems, Inc. (OTCPINK: MJLB) in online publications and other print media. Ultrack CEO Michael Marsbergen stated: "$MJLB's relationship with TELUS has benefited The Company on multiple levels. Firstly, TELUS' technology was the right fit for Ultrack's suite of products and services. Ultrack's partnership with TELUS has made everything we offer better, faster, and more affordable to our subscriber base. Secondly, TELUS has also worked hand-inhand with our design team to understand the nature of our business and develop scalable, custom solutions that benefit both us and them and that will carry us into the future. Finally, I trust that it is obvious to our shareholder base that this kind of professional exposure and validation from a major $25 billion dollar company like TELUS lets the investing public knowin no uncertain terms that $MJLB is a very real and established company that is moving forward in the most cutting-edge ways possible."

Our new biotech feature Cardio Mapping report could skyrocket overnight READ MORE
Copy and paste to browser may be required  https://tradersnewssource.com/dynamic-biotech-coverage/

Disclosure
 
Traders News Source LLC (TNS) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering small and micro-cap equity markets. TNS has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE, NASDAQ, and OTC exchanges. The other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Sponsored content, compensation if any is listed in our disclosures under any article or report that mentions a ticker symbol that we have received compensation to advertise.
 
PRESS RELEASE PROCEDURES
 
TNS LLC provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written, and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author per the procedures outlined by TNS. TNS is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents, or reports. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
 
NO WARRANTY
 
TNS, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake, or shortcoming. No liability is accepted whatsoever for any direct, indirect, or consequential loss arising from the use of this document. TNS, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, TNS, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness, or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
 
NOT AN OFFERING
 
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither TNS nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://www.tradersnewssource.com.
 
For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer be featured on our coverage list, contact us via email at: editor@tradersnewssource.com
 

CONTACT: editor@tradersnewssource.com
SOURCE: Traders News Source